216 related articles for article (PubMed ID: 15812606)
21. Celecoxib as an Adjuvant to Fluvoxamine in Moderate to Severe Obsessive-compulsive Disorder: A Double-blind, Placebo-controlled, Randomized Trial.
Shalbafan M; Mohammadinejad P; Shariat SV; Alavi K; Zeinoddini A; Salehi M; Askari N; Akhondzadeh S
Pharmacopsychiatry; 2015 Jul; 48(4-5):136-40. PubMed ID: 25959196
[TBL] [Abstract][Full Text] [Related]
22. [Efficacy of fluvoxamine combined with extended-release methylphenidate on treatment-refractory obsessive-compulsive disorder].
Zheng H; Jia F; Guo G; Quan D; Li G; Huang H
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2018 Nov; 43(11):1230-1235. PubMed ID: 30643068
[TBL] [Abstract][Full Text] [Related]
23. A prospective study of alexithymia in obsessive-compulsive patients treated with multimodal cognitive-behavioral therapy.
Rufer M; Hand I; Braatz A; Alsleben H; Fricke S; Peter H
Psychother Psychosom; 2004; 73(2):101-6. PubMed ID: 14767152
[TBL] [Abstract][Full Text] [Related]
24. Minocycline combination therapy with fluvoxamine in moderate-to-severe obsessive-compulsive disorder: A placebo-controlled, double-blind, randomized trial.
Esalatmanesh S; Abrishami Z; Zeinoddini A; Rahiminejad F; Sadeghi M; Najarzadegan MR; Shalbafan MR; Akhondzadeh S
Psychiatry Clin Neurosci; 2016 Nov; 70(11):517-526. PubMed ID: 27488081
[TBL] [Abstract][Full Text] [Related]
25. A randomized controlled trial of Japanese patients with obsessive-compulsive disorder--effectiveness of behavior therapy and fluvoxamine.
Nakatani E; Nakagawa A; Nakao T; Yoshizato C; Nabeyama M; Kudo A; Isomura K; Kato N; Yoshioka K; Kawamoto M
Psychother Psychosom; 2005; 74(5):269-76. PubMed ID: 16088264
[TBL] [Abstract][Full Text] [Related]
26. Parental obsessive-compulsive disorder as a prognostic factor in a year long fluvoxamine treatment in childhood and adolescent obsessive-compulsive disorder.
Yaryura-Tobias JA; Grunes MS; Walz J; Neziroglu F
Int Clin Psychopharmacol; 2000 May; 15(3):163-8. PubMed ID: 10870874
[TBL] [Abstract][Full Text] [Related]
27. One-Year Outcome for Responders of Cognitive-Behavioral Therapy for Pediatric Obsessive-Compulsive Disorder.
Højgaard DRMA; Hybel KA; Ivarsson T; Skarphedinsson G; Becker Nissen J; Weidle B; Melin K; Torp NC; Valderhaug R; Dahl K; Mortensen EL; Compton S; Jensen S; Lenhard F; Thomsen PH
J Am Acad Child Adolesc Psychiatry; 2017 Nov; 56(11):940-947.e1. PubMed ID: 29096776
[TBL] [Abstract][Full Text] [Related]
28. Differences between early and late drop-outs from treatment for obsessive-compulsive disorder.
Aderka IM; Anholt GE; van Balkom AJ; Smit JH; Hermesh H; Hofmann SG; van Oppen P
J Anxiety Disord; 2011 Oct; 25(7):918-23. PubMed ID: 21664103
[TBL] [Abstract][Full Text] [Related]
29. Ondansetron or placebo in the augmentation of fluvoxamine response over 8 weeks in obsessive-compulsive disorder.
Heidari M; Zarei M; Hosseini SM; Taghvaei R; Maleki H; Tabrizi M; Fallah J; Akhondzadeh S
Int Clin Psychopharmacol; 2014 Nov; 29(6):344-50. PubMed ID: 24850229
[TBL] [Abstract][Full Text] [Related]
30. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control.
Yousefzadeh F; Sahebolzamani E; Sadri A; Mortezaei A; Aqamolaei A; Mortazavi SH; Shalbafan MR; Ghaffari S; Alikhani R; Mousavi SB; Naderi S; Shamabadi A; Jalilevand S; Akhondzadeh S
Int Clin Psychopharmacol; 2020 Sep; 35(5):254-262. PubMed ID: 32541380
[TBL] [Abstract][Full Text] [Related]
31. Limited therapeutic effect of addition of buspirone in fluvoxamine-refractory obsessive-compulsive disorder.
McDougle CJ; Goodman WK; Leckman JF; Holzer JC; Barr LC; McCance-Katz E; Heninger GR; Price LH
Am J Psychiatry; 1993 Apr; 150(4):647-9. PubMed ID: 8465885
[TBL] [Abstract][Full Text] [Related]
32. Telephone cognitive-behavioral therapy for adolescents with obsessive-compulsive disorder: a randomized controlled non-inferiority trial.
Turner CM; Mataix-Cols D; Lovell K; Krebs G; Lang K; Byford S; Heyman I
J Am Acad Child Adolesc Psychiatry; 2014 Dec; 53(12):1298-1307.e2. PubMed ID: 25457928
[TBL] [Abstract][Full Text] [Related]
33. Mindfulness-based cognitive therapy (MBCT) in patients with obsessive-compulsive disorder (OCD) and residual symptoms after cognitive behavioral therapy (CBT): a randomized controlled trial.
Külz AK; Landmann S; Cludius B; Rose N; Heidenreich T; Jelinek L; Alsleben H; Wahl K; Philipsen A; Voderholzer U; Maier JG; Moritz S
Eur Arch Psychiatry Clin Neurosci; 2019 Mar; 269(2):223-233. PubMed ID: 30446822
[TBL] [Abstract][Full Text] [Related]
34. Naturalistic course of obsessive compulsive disorder and comorbid depression. Longitudinal results of a prospective follow-up study of 74 actively treated patients.
Zitterl W; Demal U; Aigner M; Lenz G; Urban C; Zapotoczky HG; Zitterl-Eglseer K
Psychopathology; 2000; 33(2):75-80. PubMed ID: 10705250
[TBL] [Abstract][Full Text] [Related]
35. Cognitive-behavioural therapy augments the effects of deep brain stimulation in obsessive-compulsive disorder.
Mantione M; Nieman DH; Figee M; Denys D
Psychol Med; 2014 Dec; 44(16):3515-22. PubMed ID: 25065708
[TBL] [Abstract][Full Text] [Related]
36. No talking, just writing! Efficacy of an Internet-based cognitive behavioral therapy with exposure and response prevention in obsessive compulsive disorder.
Herbst N; Voderholzer U; Thiel N; Schaub R; Knaevelsrud C; Stracke S; Hertenstein E; Nissen C; Külz AK
Psychother Psychosom; 2014; 83(3):165-75. PubMed ID: 24732962
[TBL] [Abstract][Full Text] [Related]
37. Extended-release fluvoxamine and improvements in quality of life in patients with obsessive-compulsive disorder.
Koran LM; Bromberg D; Hornfeldt CS; Shepski JC; Wang S; Hollander E
Compr Psychiatry; 2010; 51(4):373-9. PubMed ID: 20579510
[TBL] [Abstract][Full Text] [Related]
38. Comparing the Effects of a Herbal Drug based on
Noras MR; Soltanifar A; Salari R; Jarahi L; Abrishami MH
Curr Drug Discov Technol; 2022; 19(5):e240622206368. PubMed ID: 35748547
[TBL] [Abstract][Full Text] [Related]
39. Benefits of cognitive-behavioural therapy for children and youth with obsessive-compulsive disorder: re-examination of the evidence.
O'Kearney R
Aust N Z J Psychiatry; 2007 Mar; 41(3):199-212. PubMed ID: 17464701
[TBL] [Abstract][Full Text] [Related]
40. Fluvoxamine open-label treatment of adolescent inpatients with obsessive-compulsive disorder or depression.
Apter A; Ratzoni G; King RA; Weizman A; Iancu I; Binder M; Riddle MA
J Am Acad Child Adolesc Psychiatry; 1994; 33(3):342-8. PubMed ID: 8169178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
